Elite Pharmaceuticals (ELTP)
Bull Thesis
- Explosive profit turnaround: FY2026 revenues surged 77.1% to $148.9M and the company swung to $44.9M net income from a $(4.3M) net loss in FY2025.1
- Multiple new product launches: Generic Vyvanse (lisdexamfetamine), Tylenol with Codeine, Norco, Percocet, Methotrexate, plus Naltrexone and Phentermine rebranded under Elite label drove the FY2026 surge.1
- Rock-solid balance sheet: Cash +163% to $29.8M; long-term debt −20% to $4.7M; current ratio 6.45 and D/E of just 0.06.2
- Strategic optionality: Management engaged a bank to explore M&A, Nasdaq uplisting (targeted by Feb 2027), and potential acquisition by a foreign company seeking U.S. manufacturing amid tariff pressure.3
- $26B anticoagulant opportunity: ANDA filed with FDA in June 2026 targeting a generic of a product with $26B in annual U.S. branded sales; no generic currently exists on market.4
Bear Thesis
- Vyvanse cliff already materializing: Q1 FY2027 revenue fell 19.5% to $32.4M and operating income dropped 65% YoY due to competitive pricing pressure on generic lisdexamfetamine.5
- Micro-cap OTC illiquidity: Trading on OTCQB with no formal analyst coverage; prone to information gaps, retail speculation, and wide bid-ask spreads.6
- Severe dilution: 1.08B shares: Per-share metrics are structurally compressed — $44.9M net income yields only $0.04 basic EPS. Future equity issuances could dilute further.2
- Product concentration risk: FY2026 revenue spike was heavily first-mover Vyvanse; operating income declined 65% in Q1 FY2027 as that advantage eroded within one year.5
- Anticoagulant is pre-revenue: The $26B ANDA faces unexpired branded patents and exclusivities; commercialisation is uncertain and targeting 2028 at earliest.7
Executive Summary
Elite Pharmaceuticals (OTCQB: ELTP) is a Northvale, New Jersey–based specialty generic pharmaceutical company focused on oral controlled-release and abuse-deterrent drug formulations, incorporated in Nevada and established in October 1997.8 The company operates a single U.S. Drug Enforcement Administration (DEA)-registered manufacturing facility and develops products via Abbreviated New Drug Applications (ANDAs) for generic drugs, selling to wholesale distributors, retail pharmacy chains, and government agencies.9
The company’s financial trajectory from FY2022 through FY2026 tells a dramatic growth story: revenues grew from $32.3M in FY2022 to $148.9M in FY2026 — a more than fourfold increase in four years — while the company moved from persistent losses to its first substantial profit: net income of $44.9M in FY2026 against a net loss of $(4.3M) in FY2025.1 The key growth engine was the early-2025 launch of generic lisdexamfetamine dimesylate (branded Vyvanse), an ADHD medication whose branded version had approximately $4.3B in annual U.S. sales for the twelve months ending October 2024.10 Elite captured approximately 8–10% of the generic market from more than a dozen approved competitors. However, the Q1 FY2027 earnings report (August 13, 2026) confirmed that this advantage is eroding rapidly: revenues fell 19.5% year-over-year and operating income dropped 65%.5
The bull case rests on pipeline depth, Elite’s DEA-registered controlled-substance manufacturing moat, the June 2026 ANDA for a blockbuster anticoagulant generic targeting $26B in branded sales, and a clean balance sheet with $29.8M cash and only $4.7M in debt that enables M&A or Nasdaq uplisting.43 The bear case hinges on whether Elite can replace the Vyvanse revenue cliff with new product launches before margins compress further, the highly diluted 1.08B share count suppressing per-share returns, and the reality that the anticoagulant generic payout is years away and blocked by unexpired patents.57
Company History & Leadership
Elite Pharmaceuticals, Inc. was incorporated in Nevada and established in October 1997.8 Headquartered in Northvale, New Jersey, the company operates from a single DEA-registered manufacturing facility, giving it the capability to develop, manufacture, and sell controlled substances — a structural advantage that limits competition in certain product categories.9 Elite initially focused on abuse-deterrent opioid technology and niche generic oral controlled-release drugs before pivoting toward a broader generic portfolio strategy that accelerated after FY2023.
Leadership
| Name | Title | Background |
|---|---|---|
| Nasrat Hakim | Chairman, President & CEO | 30+ years pharmaceutical industry experience. Former International VP of Quality Assurance at Actavis (25 sites, 3,000+ employees); founded Mikah Pharma, LLC in 2009; appointed CEO August 2013; Chairman since 2016.13 |
| CFO (name not disclosed) | Chief Financial Officer | Position held since 2023 per available sources; detailed executive biography not disclosed in public filings reviewed.8 |
Business Model & Unit Economics
Elite Pharmaceuticals manufactures and sells oral, controlled-release generic and branded pharmaceuticals from its single Northvale, NJ facility. The company operates across two regulatory segments: Abbreviated New Drug Applications (ANDAs) for generic drugs and New Drug Applications (NDAs) for branded formulations.9
Revenue Lines
Revenue derives almost entirely from product sales to wholesale distributors, retail pharmacy chains, and government agencies. Key product categories include:
- ADHD/CNS: Lisdexamfetamine dimesylate capsules (generic Vyvanse) — the dominant revenue driver in FY2025–2026; Adderall XR-type amphetamine ER formulations.10
- Pain Management / Controlled Substances: Oxycodone/Acetaminophen (generic Percocet / Norco); Tylenol with Codeine; methadone hydrochloride; naltrexone HCl 50 mg.1
- Bariatric / Metabolic: Phentermine (Adipex-P / Bontril generics) for weight management, brought back under Elite’s own label in FY2026.1
- Oncology / Specialty: Methotrexate; Loxapine (antipsychotic).9
- Neurology: Ropinirole ER (generic Requip XL, launched August 4, 2026).17
Structural Advantages
Elite’s DEA-registered manufacturing facility is a meaningful structural differentiator. Obtaining and maintaining DEA Schedule II–IV controlled substance manufacturing registration involves significant regulatory burden, limiting the number of qualified manufacturers for products like lisdexamfetamine and oxycodone/acetaminophen relative to standard generics.9 Elite also holds expertise in controlled-release oral drug delivery formulation, providing a platform applicable across multiple therapeutic categories and enabling it to target complex generics where fewer competitors qualify.
Unit Economics
Elite’s operating margins expanded dramatically in FY2026: operating income of $49.1M on $148.9M revenue (33% margin) versus $19.6M on $84.0M (23% margin) in FY2025, driven by the high-margin generic Vyvanse and a shift to direct sales of Naltrexone and Phentermine under the Elite label.1 However, Q1 FY2027 showed sharp compression: operating income fell 65% to $7.5M on $32.4M revenue (23% margin) as Vyvanse generic pricing normalised amid more than a dozen competitors in the market.5
Growth Motion
Elite’s strategy is serial ANDA filings targeting niche generics in controlled substances or complex drug delivery, aiming to be an early entrant when a new generic market opens — capturing premium pricing before others crowd in. The $26B anticoagulant ANDA filed in June 2026 represents the largest single opportunity Elite has targeted to date, though it requires navigating unexpired patents and exclusivities, with management guiding toward a 2028 launch target at the earliest.7
Price History & Technicals
| Metric | Value | Notes / Source |
|---|---|---|
| Last Close (~Aug 14, 2026) | $0.31 | OTCQB18 |
| 52-Week High | $0.74 | Around Aug 202518 |
| 52-Week Low | $0.27 | Recent trough18 |
| 2025 Year Open / Close | $0.55 / $0.54 | 2025 high $0.55, low $0.3218 |
| 2024 Annual Range | $0.12–$0.71 | Full year 2024; +285.7% YoY gain18 |
| Shares Outstanding (Diluted) | ~1.08 billion | FY2026 weighted-average2 |
| Market Cap | ~$335M | At $0.31 × 1.08B shares |
| Exchange | OTCQB | Not listed on major exchange6 |
| Short Interest | 2.03M shares | ~0.24% of float — minimal19 |
ELTP’s stock history in 2024–2026 mirrors the company’s operating trajectory: a dramatic multi-year rally followed by a significant post-earnings correction. In 2024, the stock rose approximately 285.7%, from a low of $0.12 to a high of $0.71, as investor sentiment began pricing in the pending generic Vyvanse launch.18 The stock sustained gains around $0.54–$0.55 at year-end 2024 and into early 2025, then spiked to a 52-week high near $0.74 around August 2025 as FY2025 revenue momentum became apparent.
After record FY2026 annual results were reported in late June 2026, the stock paradoxically declined — shares lost 13.7% in the weeks following the earnings report, underperforming the S&P 500 (which gained 1.8% over the same period) by approximately 15.5 percentage points.20 This “sell the news” dynamic is common in small-cap generics when a growth catalyst is already priced in. The Q1 FY2027 results (August 13, 2026) confirmed the market’s concern: Vyvanse pricing pressure was real and the YoY comparison would be challenging for the foreseeable future.5
At $0.31, ELTP trades at an implied trailing P/S of roughly 2.2× based on FY2026 revenues of $148.9M and a ~$335M market cap. The technical picture, per StockInvest.us as of August 7, 2026, carries a “Sell Candidate” rating with a technical score of −1.34, with both short- and long-term moving averages negative.21 Short interest is minimal at 2.03M shares (approximately 0.24% of float), indicating no meaningful short thesis from institutional players — consistent with the lack of formal coverage.19
Financial Statements & Guidance
Annual Income Statement (Fiscal Years Ending March 31)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $32.3M | $34.2M | $56.6M | $84.0M | $148.9M |
| YoY Growth | — | +5.9% | +65.7% | +48.4% | +77.1% |
| Operating Income | not disclosed | not disclosed | not disclosed | $19.6M | $49.1M |
| Net Income (Loss) | not disclosed | not disclosed | not disclosed | $(4.3M) | $44.9M |
| EPS (Basic) | not disclosed | not disclosed | not disclosed | ~$0.00 | $0.04 |
| EPS (Diluted) | not disclosed | not disclosed | not disclosed | ~$0.00 | $0.03 |
FY2022–FY2024 operating income and net income not found in available sources. Sources: 115
Most Recent Quarter: Q1 FY2027 (ended June 30, 2026)
| Metric | Q1 FY2027 | Q1 FY2026 | Change |
|---|---|---|---|
| Revenue | $32.4M | $40.3M | −19.5% |
| Operating Income | $7.5M | $21.7M | −65.4% |
| Net Income | $5.9M | not disclosed | — |
Source: 5
Balance Sheet (March 31, 2026 — FY2026 Year-End)
- Cash & Equivalents: $29.8M (+163% from $11.3M in FY2025)1
- Long-Term Debt: $4.7M (−20% from $5.8M in FY2025)2
- Current Ratio: 6.452
- Debt/Equity: 0.062
- Shares Outstanding (Diluted): 1.08 billion2
Cash Flow
- FY2026 Operating Cash Flow: $23.7M (+219% from $7.5M in FY2025)1
- Net Cash Increase FY2026: +$18.5M (+163% YoY)1
Forward Guidance
Management did not provide specific FY2027 revenue guidance. On the Q4 FY2026 call (June 2026), CEO Hakim cautioned that growth rates may moderate as the revenue base expands and that Vyvanse pricing is becoming more competitive. Management cited 3 drugs pending FDA approval and 4+ products in bioequivalence study as potential future revenue contributors but declined to specify dollar amounts.11 Q1 FY2027 revenue of $32.4M, annualised, implies a FY2027 run-rate of approximately $130M — roughly 13% below FY2026’s $148.9M — consistent with revenue normalisation rather than collapse, though management noted results are “in line with the three prior quarters.”5
Sell-Side View
Elite Pharmaceuticals has no formal sell-side analyst coverage.22 As an OTCQB-traded micro-cap, the company does not meet the coverage thresholds of major brokerages. There are no consensus ratings, no formal price targets, and no EPS estimates from Wall Street firms in any standard aggregator.
The absence of analyst coverage is both a risk and an opportunity factor. On the risk side: without institutional research, price discovery is less efficient and the stock is more vulnerable to information asymmetry and retail-driven speculation. Message boards (InvestorsHub/ADVFN) serve as the primary investor discussion venue, which can introduce noise uncorrelated with fundamentals. On the opportunity side: any future analyst initiation — likely contingent on a Nasdaq uplisting — could serve as a significant positive catalyst, and the story has not yet been “discovered” by the broader institutional investment community.
Algorithmic and AI-based forecasting services have published price targets for ELTP, but these are model-driven outputs, not independent fundamental research. StockInvest.us rated ELTP a “Sell Candidate” with a technical score of −1.34 as of August 7, 2026, citing negative signals from both short- and long-term moving averages.21 StockScan’s predictive model set an average 2026 price estimate of $0.0523 with a peak of $0.0698 — figures that appear to use pre-2026 data models not reflecting the company’s actual FY2026 financial performance, and should be treated with extreme caution.23
The path to sell-side coverage most plausibly runs through a Nasdaq uplisting, which management has targeted by February 2027.3 Until that milestone, investors must rely on company SEC filings, earnings press releases, and conference call transcripts for all fundamental data.
Partnerships, Customers & Suppliers
Elite’s DEA registration permits manufacture of Schedule II–IV controlled substances — a prerequisite for its opioid, stimulant, and addiction-treatment portfolio and a significant barrier to entry for potential competitors.9
Elite sells through wholesale pharmaceutical distributors and directly to retail chains. Bringing Naltrexone and Phentermine under the Elite label in FY2026 shifted volume from distributor-margin to direct Elite revenue, improving per-unit margins.1
Elite regularly references IQVIA market data to size addressable markets for ANDA filings and to announce product launches (e.g., $26B anticoagulant market, $22M methadone retail market, $10M Requip XL market).41617
Elite has engaged an investment bank for M&A advisory. CEO Hakim stated the company is evaluating staying on OTC, merging, acquiring, being acquired, or uplisting. Proposed U.S. tariffs on generic drugs would make Elite an attractive acquisition target for foreign generics seeking a U.S. manufacturing base.3
FDA approval is the gating factor for each new product launch. As of mid-2026, Elite had 3 ANDAs pending FDA approval and 4+ products in bioequivalence study, forming the next-generation revenue pipeline.11
Naltrexone (opioid and alcohol addiction treatment) and methadone (maintenance therapy) are sold through government and institutional procurement channels in addition to retail pharmacy, providing a government-demand backstop for key products.12
Elite does not disclose revenue concentration by customer in available public sources; no single wholesale or retail customer has been named as accounting for a material share of revenues. The partnership ecosystem is primarily regulatory (DEA, FDA) and distribution-based rather than technology or IP-licensing partnerships with named counterparties.
Competition
Elite competes in the U.S. generic pharmaceutical market, specifically within the niche of controlled-release and controlled-substance oral dosage forms. The company’s structural moat is its DEA-registered manufacturing facility, but within each individual ANDA-approved product it faces multiple competitors once a generic is approved. The lisdexamfetamine market — Elite’s largest FY2026 revenue contributor — had more than a dozen approved generic manufacturers competing on price by 2026, which directly contributed to the margin compression in Q1 FY2027.5
| Company | Public/Private | Scale / Differentiator | Overlap With ELTP |
|---|---|---|---|
| Teva Pharmaceutical | Public (TEVA) | Global generic giant; top-3 U.S. generic by revenue | Lisdexamfetamine ANDA; multiple overlapping generics |
| Amneal Pharmaceuticals | Public (AMRX) | Large U.S. specialty generic; controlled-substance capability | Competing in overlapping ANDA product categories |
| Mallinckrodt | Public (MNK) | Specialty pharma; DEA-licensed; pain/CNS focus | Direct overlap in opioids and CNS controlled substances |
| Lannett Company | Public (LCI) | Mid-size U.S. generic manufacturer; similar niche positioning | Compared by Zacks as a peer; similar market segment24 |
| Takeda / Shire (Vyvanse brand) | Public (TAK) | Original Vyvanse brand; patent expiry opened the generic market | Brand loss of exclusivity powered Elite’s FY2025–2026 growth |
The generic pharmaceutical market is structurally commoditised once a product has multiple approved ANDAs. Elite’s advantage narrows to: (1) being an early entrant when a new generic market opens, capturing premium pricing before others crowd in; and (2) targeting markets where manufacturing complexity or DEA scheduling limits competition. The company’s strategy of filing ANDAs for controlled-substance or complex generics before patent expiry — as with the anticoagulant ANDA — attempts to extend this playbook to larger markets.
The key competitive risk is scale: larger generic players can underprice Elite on products where they have manufacturing cost advantages, and their financial resources allow sustained price competition. The Q1 FY2027 results demonstrated this dynamic starkly: even as Elite’s volume in lisdexamfetamine held or grew, the per-unit price fell enough to drive a 65% decline in operating income.5
Risks & the Bear Case
A substantial portion of FY2026 revenue derived from generic lisdexamfetamine. Q1 FY2027 operating income fell 65% as pricing eroded. If pipeline products cannot offset this loss, revenue and margins will compress materially.5
With 1.08 billion diluted shares, per-share EPS of $0.03–$0.04 on $44.9M net income reflects severe dilution. Future equity issuances for M&A or capex could dilute further; per-share value is structurally compressed.2
Trading on OTCQB with no formal analyst coverage; ELTP is illiquid relative to exchange-listed peers. Retail-driven price discovery, wide spreads, and limited institutional participation create information asymmetry and manipulation risk.6
The $26B anticoagulant ANDA faces unexpired branded patents and exclusivities. FDA approval, patent challenges, and commercialisation timing are all uncertain; management targets 2028 but that could slip significantly.7
Generic drug markets face systematic price erosion as more ANDAs are approved. Elite participates in markets with more than a dozen competitors per individual product; sustained price normalisation is an ongoing gross margin headwind.5
All operations run from a single Northvale, NJ facility. Any manufacturing disruption — regulatory shutdown, fire, contamination, supply chain failure — would halt all production and revenue.9
Controlled substance manufacturing is subject to DEA quotas, scheduling decisions, and inspections. Adverse regulatory actions or loss of DEA registration would eliminate Elite’s primary competitive differentiator and most of its product portfolio.9
Management is simultaneously exploring staying OTC, M&A, and uplisting — creating execution risk. Resources divided across strategies may dilute focus; a failed acquisition or unfavourable merger could permanently alter the company’s trajectory.3
Bear Thesis Deep Dive
The core bear case on ELTP is a “one-drug wonder” thesis: the company’s FY2025–2026 financial transformation was overwhelmingly driven by a first-mover window in generic lisdexamfetamine, and that window has now substantially closed. The Q1 FY2027 earnings report (August 13, 2026) is the first concrete data point confirming this: revenues fell 19.5% and operating income dropped 65% year-over-year, “primarily attributed to lower margins realized from sales of Elite’s generic Vyvanse product line.”5
At 1.08 billion shares outstanding, even FY2026’s record net income of $44.9M yields only $0.04 of basic EPS — implying a P/E of roughly 7–8× at current prices, which appears cheap, but only if those earnings are recurring. The bear case argues they are not: Vyvanse revenue contribution will continue compressing as more competitors capture market share and per-unit pricing normalises across the generic ADHD market. The pipeline replacements (Requip XL at $10M addressable market, methadone at $22M market) are far smaller than what Vyvanse contributed — meaning the company faces a multi-year revenue and margin trough while awaiting its next large catalyst.1716
The anticoagulant ANDA, while exciting in scale ($26B branded market), represents a multi-year pre-revenue bet involving patent litigation risk and regulatory uncertainty.4 Investors are being asked to pay for FY2026 earnings that may not recur while waiting for a product that may not launch until 2028 or later — in a company trading on the OTCQB with no institutional oversight. The stock’s 13.7% decline following record FY2026 earnings suggests the market partially prices this dynamic in, but the full mean-reversion of operating margins from 33% (FY2026) back toward 20–25% may not yet be fully reflected at current prices.20
Catalysts — Recent & Upcoming
Recent Catalysts (June–August 2026)
Upcoming Watch List
| Event | Timing | Significance |
|---|---|---|
| Q2 FY2027 Earnings (quarter ended Sept 30, 2026) | ~Nov 2026 | Will confirm or refute revenue stabilisation at $30–35M/quarter; key margin data point for the post-Vyvanse trajectory.5 |
| Nasdaq Uplisting | Target: Feb 2027 | Management has set February 2027 as the target for Nasdaq uplisting, which would broaden the investor base and enable formal analyst coverage initiation.3 |
| 3 Pending ANDA Approvals | 12–24 months (typical) | FDA approvals of 3 pending ANDAs could open new revenue streams; each approval is a potential positive catalyst.11 |
| M&A / Strategic Transaction | Unknown | Management has hired a bank; outcome could be acquisition, merger, or status quo — binary for the stock.3 |
| Anticoagulant ANDA Progress | Target: ~2028 | FDA correspondence, paragraph IV certification, or patent litigation developments on the anticoagulant ANDA would be material news; management targets 2028 commercial launch.7 |
References
- Elite Pharma FY2026 revenue rises to $148.9M StockTitan / Elite Pharmaceuticals 8-K · July 2026
- Elite Pharmaceuticals (ELTP) Statistics & Valuation Metrics StockAnalysis.com · 2026
- Elite outlines 2028 anticoagulant launch target as NASDAQ uplisting progresses Seeking Alpha · 2026
- Elite Pharmaceuticals Announces Filing of ANDA for Generic Anticoagulant Product Newsfilecorp.com / Elite Pharmaceuticals Press Release · June 1, 2026
- Elite Pharmaceuticals Announces Q1 Fiscal 2027 Revenue of $32.4 Million Kalkine Media / Elite Pharmaceuticals Press Release · August 13, 2026
- ELTP Profile — Elite Pharmaceuticals, Inc. OTC Markets · 2026
- Elite outlines 2028 anticoagulant launch target as NASDAQ uplisting progresses (anticoagulant patent/exclusivity context) Seeking Alpha · 2026
- Elite Pharmaceuticals (ELTP) Company Profile & Description StockAnalysis.com · 2026
- About Elite Pharma Inc (ELTP) — Company Profile Investing.com · 2026
- Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse Yahoo Finance / Elite Pharmaceuticals Press Release · 2025
- Elite Pharmaceuticals Reports Q4 2026 Results: Full Earnings Call Transcript Benzinga · July 2026
- ELITE PHARMACEUTICALS INC /NV/ — Form 8-K — Naltrexone FDA Approval SEC EDGAR · January 2013
- Elite Pharmaceuticals, Inc. Appoints Nasrat Hakim as President and CEO GlobeNewswire · August 5, 2013
- Elite Pharmaceuticals Launches Generic Methadone Tablets GlobeNewswire · November 5, 2018
- Elite Pharmaceuticals (ELTP) Annual Revenue History StockAnalysis.com · 2026
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets (April 2026) Yahoo Finance / Elite Pharmaceuticals Press Release · April 2026
- Elite Launches Generic Requip XL in Five Strengths StockTitan · August 4, 2026
- Elite Pharmaceuticals — 27 Year Stock Price History MacroTrends · 2026
- ELTP Short Interest Data Fintel.io · 2026
- Elite Pharmaceuticals Stock Slips Despite Record Fiscal 2026 Earnings Yahoo Finance · July 2026
- Elite Pharmaceuticals Stock Price Forecast — StockInvest.us StockInvest.us · August 2026
- Elite Pharmaceuticals, Inc. (ELTP) Analyst Ratings, Estimates & Forecasts Yahoo Finance · 2026
- ELTP Stock Forecast — StockScan StockScan.io · 2026
- ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy? Zacks via TradingView · 2026